Efficacy of ACE Retino and Cataclear in Treating Adult Corneal Opacity

Corneal opacity, a major global cause of visual impairment, often requires invasive treatments such as keratoplasty, which carry risks like graft rejection. Adults face added challenges due to limited regenerative capacity, emphasizing the need for non-surgical, targeted therapies. This study assesses the efficacy of ACE Retino (sublingual/topical peptides) and Cataclear (topical drops) in reversing advanced corneal opacity in a 27-year-old male. Over 90 days, treatment adherence was digitally monitored, while biomarkers (IL-1β, collagen III, SOD2) and imaging (OCT, pachymetry) evaluated therapeutic outcomes. The patient showed a 92% restoration of corneal clarity, visual acuity improvement (from < 0.1 to 0.4), 23% reduction in central corneal thickness, and marked molecular improvements (TGF-β1: −65%, collagen III: −75%, SOD2: +133%). Cataclear accelerated epithelial regeneration (85% scratch closure). With 96% adherence, surgical intervention was avoided. These findings suggest potential therapeutic synergy of ACE Retino and Cataclear as non-invasive agents for corneal opacity management. However, broader validation is required (NCT06787482) .